Skip to content
  • Education Center
  • Vital
  • Shop
Site Logo
  • Podcasts
  • Articles
  • Events
  • About

Subscribe to Our Podcast

Post Tag: Business

Posted on February 7, 2023February 7, 2023

PT387 – Psychedelic Ethics & Self-Reflexivity and Proposition 122 Conflict & Resolution

In this episode, Joe interviews Jessica “Jaz” Cadoch: anthropologist, Co-Director of the Global Psychedelic Society, and Prop 122 steering committee member; and Sovereign Oshumare: Founder of XRYSALIS, an online community and retreat for queer, transgender, and intersex people of color, and Founder of Shelterwood Collective, a 900-acre eco-village and retreat center led by LGBTQ Black and Indigenous people.

Together, they are Co-Founders of ALKEMI, a consulting firm for psychedelic ethics and accountability, created due to the amount of businesses coming into this space who likely have very little understanding of the values that were established while they weren’t paying attention. They’re asking businesses questions many don’t consider: Is there a true need for them? Do they know their community and does the community want them there? Are their internal operations hierarchal or decentralized? Do employees feel heard and seen? And most importantly, have they taken any of the lessons from psychedelics and applied them towards the way they handle business and treat each other? 

As Cadoch was a member of the steering committee for Colorado’s Natural Medicine Act (AKA Prop 122), she discusses what it was like from the inside: the problems (complaints about who was involved, if the voices from the community were a true representation, language in the bill); how the conflict showed how easily money and power could embody people; the problems with fighting over perfection while people are being sentenced to prison; and, where everyone is now: together in the aftermath, trying to figure out how to work together, unite missions, and build bridges between seemingly disparate parties.

They also discuss the problems with binary thinking, the concept of a business recalibrating its relationship to profit and ROI, what true access means, why it’s ok to go slow and not rush through the uncomfortable, and more.

Notable Quotes

“How are you really taking the lessons that the medicines are teaching us and applying them to the way you’re building your company? …Are you doing psychedelic business or are you doing business psychedelically?” -Jaz

“Each time that I’m broken, I’m rebuilt stronger. And that, to me, is such a journey. And committing to that journey is what I hope we as ALKEMI bestow upon people; giving them the endurance and stamina to be broken and be rebuilt, because we all need that. This system needs that. This world needs that. And we live in a system where we’re rewarded for not doing it.” -Sovereign 

“At the end of the day, we are all we got. And the more we know who we are, the more we find alignment, the more we find each other, the more we mend our differences, the stronger we’ll be.” -Sovereign

“When we talk about access, it’s not only like financial access, but it’s also cultural access – to make it make sense for people who don’t speak this language, make it make sense for people who have survivor’s guilt from growing up in the hood in D.C., make it make sense for Hispanic rural communities, make it make sense for my Grandmother that needs a doctor in a white coat to tell her that this is safe. That’s what access means. It’s all of that.” -Jaz

Links

Alkemi-consulting.org

Alkemi-consulting.org: Community Needs Assessment

Mayahealth.com

Mayahealth.com: Ethics

Psychedelics Today: PT265 – Jessica Cadoch, MA – Cooperation, Drug Exceptionalism, and 12-step Programs

Xrysalis.net

Shelterwoodcollective.org

Montrealpsychedelicsociety.org

Thespore.org: Society for Psychedelic Outreach, Reform, and Education

Ballotpedia.org: New Approach PAC

Thenowaksociety.org

Psychedelic Club of Denver

Denver Mushroom Cooperative

Thespore.org: The People’s Medicine Council of Colorado

Thepsychedelicbar.org: The Psychedelic Bar Association

National Psychedelic Conference

The Structure of Scientific Revolutions, by Thomas S. Kuhn

Posted on January 24, 2023January 24, 2023

PT383 – Identity, Rage, Culture, and Venture Capital

In this episode, David interviews Raad Seraj: host of Minority Trip Report, a podcast for underrepresented views in psychedelics and mental health, and founder of Mission Club, an education and investment platform.

Seraj tells his story of growing up in Bangladesh and Saudi Arabia and eventually finding himself in Canada, and how the discomfort and rage he felt as a result of class and xenophobia affected him. He talks about the idea behind his podcast, Minority Trip Report, and how, while they need to be heard, underrepresented and BIPOC voices aren’t a monolith. And he talks about the incestuous and gatekeeping nature of venture capital and the complications of actually turning investments into lasting business. With Mission club (which is partnering with Microdose), he aims to create opportunities for people who don’t have a ton of money to invest in early stage companies in this space, to help the dreamers who don’t necessarily fit the bill for traditional VC.

And he discusses much more: David Chalmers’ theory of “The Extended Mind”; the problems with having one idea of mental health and summarizing complicated minds into little boxes; how we are made up of different selves and how psychedelics can help us to acknowledge and integrate our minority selves; the differences between anger and rage and how 5-MeO-DMT helped him shed his rage; how we can use technology, culture, and capital together to amplify what exists and build what doesn’t; the three places that have transformed him the most; and initiating a bus-wide Cyndi Lauper sing-along while on tour with Finger Eleven as a host for Much Music.

Notable Quotes

“If you talk about mental health and healing: all healing is the reintegration of the narrative landscape – the autobiographical story. But the problem is; when you only have one type of story, one type of autobiographical narrative that gets to be heard, that gets to be embedded, that gets to be shared, that gets to go viral; and from that, you build courses and infrastructure and definitions of what mental health is and then you sort of impose it on the rest of the world – that is a problem because mental health is ultimately about being a human being, and we are multipolar beings and we are forced to be summarized in very small ways, whether by society or by systems.”

“You have a part that is elevated above the body and the mind and the consciousness, and seeing and observing yourself and your truest nature and your truest needs and wants and desires and so on, and I think with people who are on the margins (again, whether you’re Jewish, whether you’re bisexual, whether you’re a person of color, whether you’re an immigrant, or whatever), the parts that you suppress the most all of a sudden find light. They can be seen; that’s where the light gets in. And then that temporary visibility of all of a sudden seeing that part of you without judgment, and being almost agnostic to those parts, is powerful.”

“I recognized very early on [that] there was class. Race came after. Race is a 400-year-old concept. Class is a permanent part of any human society, but class is so much more insidious. We don’t talk about it.”

“At the surface of everything, whether it’s culture, politics, music, tech: it’s all bullshit. There’s a thin sheen of garbage. You have to dig a little deeper to find the true stuff.”

Links

Minoritytrip.com

Missionclub.co

Your Symphony of Selves: Discover and Understand More of Who We Are, by James Fadiman, Ph.D., & Jordan Gruber, J.D.

Theculturetrip.com: Toronto Named The Most Diverse City In The World By BBC Radio

Wikipedia: Much (TV channel)

YouTube: Finger Eleven – Paralyzer

YouTube: Cyndi Lauper – Time After Time

Wikipedia: Extended mind thesis

Navalmanack.com

Angellist.com

Yahoo.com: Black women lead in starting businesses, but struggle to get funding

The Power Law: Venture Capital and the Making of the New Future, by Sebastian Mallaby

Microdose.buzz

Enthea.com

Psychedelics Today: PT376 – Ketamine and Psychedelic-Assisted Therapy as Employee Benefits, featuring Sherry Rais

Mayahealth.com

Fox4kc.com: Psychedelics Today Re-Launches Vital Diversity, Equity and Inclusion Scholarship Fund to Support Student Practitioners

Vital: Diversity, Equity & Inclusion Tuition Scholarship Access Fund

Ourcortes.com (Cortes Island)

Posted on January 13, 2023January 13, 2023

Psychedelics Weekly – Prince Harry and Psychedelics, Proposed Legalization, and The Roland R. Griffiths, Ph.D. Professorship Fund

For this week’s episode, we had plans for a guest to join Joe to talk about some legal battles, but as seems to be the norm this time of year, sickness postponed that conversation to a future date. With David taking some much-deserved time off and Kyle in Jamaica on a Vital retreat, this Psychedelics Weekly is a rarity: just Joe, monologuing the news.

It’s probably best to just listen and head to the links to follow along, but some highlights this week are: Prince Harry coming out of the psychedelic closet; Virginia lawmakers proposing the legalization of psilocybin; psychedelics legislation already in plans for nearly a dozen states in 2023; NBC news recognizing the need psychedelic therapists, facilitators, and education; the WHO aiming to rename 5-MeO-DMT to Mebufotenin; and Roland Griffiths creating The Roland R. Griffiths, Ph.D. Professorship Fund to ensure his work continues to be recognized after he passes.  

He also talks about Convergence, and you should know that prices increase on January 16, so don’t wait any longer! Check back next week for more news and, *fingers-crossed* a co-host – hopefully Kyle calling in to tell us all about the retreat!

Links

Cbsnews.com: Prince Harry says he’s used psychedelics to help cope with grief

Npr.org: On Point podcast (“Psychedelics and who should be able to use them” from 1/6)

Psychedelics Today: PT338 – Melissa Lavasani – The Power of Storytelling, The Preservation of Peyote, and “How to Change Your Mind”

Psychedelics Today: PT223 – Daniel Carcillo – Life After Sports

Psychedelicmedicinecoalition.org

Cnn.com: Chasing Life Podcast, with Dr. Sanjay Gupta – What Promise Do Psychedelics Hold As Therapeutics​​

Marijuanamoment.net: Lawmakers Are Already Pursuing Psychedelics Legislation In Nearly A Dozen States For 2023

Virginiamercury.com: Virginia lawmakers propose legalizing medicinal use of psychedelic mushroom compound psilocybin

Westword.com: Drug Record-Sealing Clinic In Wake of Colorado’s New Psychedelics Law

Cityweekly.net: Dr. Strangelove: Accused killer Dr. Robert Weitzel has a troubled career, but plenty of defenders.

Atmanretreat.com

Nbcnews.com: Psychedelic therapies are on the horizon, but who will administer the drugs?

Futurism.com: Startup Trying to test Whether People on DMT Experience a Shared Alien Universe

Dmtx.org

Psychedelics Today: Daniel McQueen – DMTx and Future Psychedelic Technologies

Twitter.com: Psychedelic Alpha: WHO Gives 5-MeO-DMT Generic Name: Mebufotenin

Tim Ferriss Show #646: Brian C. Muraresku with Dr. Mark Plotkin: The Eleusinian Mysteries, Discovering the Divine, The Immortality Key, The Pagan Continuity Hypothesis, Psychedelics, and More

Psychedelics Today: Mark Plotkin – Bio-Cultural Conservation of the Amazon

Psychedelics Today: PTSF 35 (with Brian Muraresku)

Griffithsfund.org

Hopkinspsychedelic.org

UCLA Psychedelic Studies Initiative

UCLA Psychedelic Studies Initiative’s survey: Psilocybin to treat drug addictions

Mixmag.net: New Zealand Authorities Believe 4KG of MDMA Was Flushed Down A Toilet

Psychedelics Today: Convergence

Posted on December 30, 2022January 2, 2023

Psychedelics Weekly – Psilocybin and Stress Response, the Minnesota Medical Association Endorses Decriminalization, and Scott Wiener Introduces Senate Bill 58

In this week’s episode, Joe and Kyle are together again before Kyle sets off for a 2-month road trip centered around Vital retreats, where we hope he’ll be able to report in from live while in Jamaica. 

They talk about Vital: applications are open for the April 2023 edition and close in February, so if you have questions, check out the website or attend an upcoming Q+A. And Joe and other members of the team will be at MAPS’ conference in Denver this June (use code PT15 at checkout for 15% off), as well as Cannadelic in Miami this February.  

And for the news, they highlight four stories this week: “Psilocybin induces acute and persisting alterations in immune status and the stress response in healthy volunteers,” showing that, even with a small study, long-term stress response was much lower than the placebo group; The Economist highlighting psychedelic medicines as one of the five stories to watch out for in 2023; the Minnesota Medical Association endorsing the decriminalization of drugs with a 219-34 vote, mimicking the Portugal model and saying that there is insufficient evidence to support the claim that criminal penalties for possession deter drug use; and San Francisco Senator Scott Wiener submitting a new version of his previously denied SB-519 (now SB-58) that no longer includes LSD and MDMA – modeling the more natural medicine model that we’ve seen succeed in other states. As Joe says often, we want everything and we want it now, but every step helps, as we’ve seen with recent posts about people not being sent to prison for the rest of their lives.

Links

Convergence

Vitalpsychedelictraining.com

Vital 2023: Informational Session and Q&A

Microdosing Masterclass: Investigate the history, science, and best practices for safe and effective microdosing

Psychedelicscience.org (MAPS conference, use code PT15 for 15% off)

Medrxiv.org: Psilocybin induces acute and persisting alterations in immune status and the stress response in healthy volunteers

Psychopharmacology in Maastricht’s Twitter thread about this study

Springer.com: Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning

The Economist: The World Ahead 2023: five stories to watch out for

Awaknlifesciences.com

Yahoo.com: Medicine Innovations Group Announces Closing Under Share Subscription Agreement

Marijuanamoment.net: Minnesota Medical Association Endorses Decriminalizing Drugs

Marijuanamoment.net: New Jersey Senate President Files Psilocybin Legalization Bill That Includes Home Grow Option, Unlike Current Marijuana Law

Sfgate.com: ‘Magic mushrooms’ would be decriminalized in California under new bill

Lawenforcementactionpartnership.org

Instagram: ICEERS’ post about Kat Courtney, who was sentenced to 40 years in prison in the USA for ayahuasca

Cannadelic.miami

Posted on December 23, 2022December 23, 2022

Psychedelics Weekly – Prop 122 and Data Privacy, Ending the Crack/Cocaine Sentencing Disparity, and the High Cost of Psychedelic Therapy

In this week’s episode, Kyle is back on the podcast, joining Joe to discuss three recent articles; two of which pose a lot of questions. 

They first look at Colorado’s Proposition 122, which, now that it has passed, enters into the long and arduous process of being figured out – all while existing in the complicated paradigm of state vs. federal legality. One of the biggest concerns revolves around data collection and privacy: Is the collected data truly anonymous? Since psychedelics will still be federally illegal, how can we trust that the DEA isn’t going to abuse their power? 

Next, they discuss Attorney General Merrick Garland making moves to end the sentencing disparity between offenses involving powder cocaine and crack cocaine: while essentially the same substance, being caught with 28 grams of crack cocaine currently carries the same sentencing as having 500 grams of powder!  

And lastly, they touch on a very interesting article from Lucid News about the value of psychedelic therapy, which gives some staggering data points showing why the black market will always exist: MDMA-assisted therapy sessions likely costing $11,500 (with the MDMA itself costing between $480 and $9,600), Esketamine treatments costing as much as $32,400 a year, and more – all with results that don’t seem to be as long-lasting as many believed they would be. This one deserves more analysis, but Joe and Kyle had limited time for recording this week, so stay tuned for more. For now, enjoy this episode, and Happy Holidays from the Psychedelics Today team!

Links

5280.com: Big Questions Surround the Rollout of Psychedelics in Colorado

Wired.com: Seeking Psychedelics? Check the Data Privacy Clause

Nbcnews.com: AG issues new guidance on ending sentencing disparities for crack versus powder cocaine cases

Psychedelicstoday.com: PT236 – Drugs: Honesty, Responsibility, and Logic, featuring Dr. Carl Hart

Lucid.news: Is the High Cost of Psychedelic Therapy Worth It?

Blossomanalysis.com

Tim.blog: Dennis McKenna — The Depths of Ayahuasca: 500+ Sessions, Fundamentals, Advanced Topics, Science, Churches, Learnings, Warnings, and Beyond (#523)

Posted on December 6, 2022

PT376 – Ketamine and Psychedelic-Assisted Therapy as Employee Benefits

In this episode, David interviews Sherry Rais: Executive Director of the Boston Psychedelic Research Group, Grants Manager for CIIS, and CEO/Co-Founder of Enthea.

Enthea is a benefit plan administrator that provides health plan benefit riders and single case agreement services for psychedelic healthcare with a provider network including certified and credentialed Ketamine-Assisted Therapy (KAT) and Psychedelic-Assisted Therapy (PAT) practitioners. In other words, if a company wants to offer psychedelic-assisted therapy as a benefit for their employees, Enthea makes this possible (and affordable). Their first client was the very psychedelically-minded Dr. Bronner’s Magic Soaps, and they’ve just announced the signings of three new clients that you may not expect to provide KAP to their employees: Daybreaker, Tushy, and Guinn Partners. Their goal is to have 100,000 covered lives in 40 cities by the end of 2023, and, alongside the guidance of MAPS, hopefully roll out MDMA-assisted therapy in Q2 of 2024. 

Rais talks about Enthea’s process, costs, and goals; her Ismaili religion; her nomadic, marathon-running life; her experience sleeping on the streets of Toronto at 16 and her need to help the less-fortunate; how her most powerful psychedelic experience was watching someone else transform; and why companies are suddenly interested in these emerging therapies.

Notable Quotes

“For me, the most powerful psychedelic experience I had was actually in a situation where I was sitting with someone else and saw this person transform in front of me. That was two years ago and that person; I still see the effects of that experience on that person’s life and how much he’s changed from this one experience, and I’ve never seen anything like it. It was the most beautiful thing I’ve ever witnessed.”

“I think you and I know that these medicines work, and we also know that they cost way more than $500, and immediately, that tells me there’s an equity crisis in the ecosystem; that we’ve finally found medicines that may be able to help millions of people that are suffering from a variety of issues, and there’s this huge barrier and its cost. So the goal of Enthea is to solve that problem by making these medicines affordable.”

“The fact that you have a plan that doesn’t cover mental health is very telling of the landscape and the culture in America today and why you’ve made the case for me on why Enthea is needed. Because if this doesn’t happen, when will people get access? They’ll continue waiting and waiting and waiting that their primary insurance provider covers this.”

Links

Enthea.com

Minority Trip Report Podcast: 1-7 – Sherry Rais: Social Impact, Psychedelic Therapy as Employee Benefit, and Finding Strength as a Female CEO

Bostonpsychedelicresearchgroup.com

Psychedelics Today: PT364 – Burning Man, Psychedelic Maturity, and Radical Hope, featuring: Jamie Wheal

Drbronner.com: Dr. Bronner’s to Provide Psychedelic-Therapy as Employee Healthcare Benefit

Drbronner.com: Ketamine-Assisted Therapy, A Light In The Dark

Finance.yahoo.com: Laid-off workers can now get a free month of ketamine-assisted therapy services to help with their mental health

Flowintegrativeketamine.com

Nue Life Health

Tabularasahealthcare.com

Posted on November 25, 2022December 2, 2022

Psychedelics Weekly – Bipartisan Political Movement & Psychedelics and Pain

This week features David Drapkin, Joe Moore (for the first part), and introduces Alexa Jesse, who you’ve probably heard in ads, but who makes her first appearance on the podcast. 

They discuss two big political moves in the advancement of psychedelics: the creation of the Congressional Psychedelics Advancing Clinical Treatments (PACT) Caucus (led by Representatives Lou Correa (D-CA) and Jack Bergman (R-MI)), and the filing of the Breakthrough Therapies Act by Senators Cory Booker (D-NJ) and Rand Paul (R-KY).

And they talk about the story of Jim Harris overcoming paralyzation through psilocybin; NICE (National Institute for Health and Care Excellence) determining that Esketamine is not cost-effective; new progress in Germany and Finland; MDMA-assisted therapy (and other psychedelics) showing alleviation of chronic pain; a ramp up in LSD research for Alzheimer’s studies; and more.

Plus, we hear a bit of Alexa’s story, wish Joe and Johanna happy birthdays, and talk about what’s most immediate in the PT world: Early Bird pricing ending today for our first conference, Convergence (use code PTINSIDER10 for a 10% discount!), and the next round of Navigating Psychedelics launching next week. 

 

Links

Bipartisan Lawmakers Form New Psychedelics Caucus In Congress (Marijuana Moment)

Psychedelicmedicinecoalition.org

House Lawmakers Launch Bipartisan Psychedelics Caucus (High Times)

Jim Harris Was Paralyzed. Then He Ate Magic Mushrooms (Outside Online)

Surprising Results: Psilocybin Trial for Depression Alleviates Chronic Pain (Psychedelics Today)

Why Did Psychedelics Relieve My Chronic Pain? (Psychedelics Today)

Chronic Pain and Phantom Limb Pain: Could Psilocybin Be the Answer? featuring: Timothy Furnish, MD & Joel Castellanos, MD (Psychedelics Today)

National Institute for Health and Care Excellence (NICE): Esketamine nasal spray for treatment-resistant depression

MDMA-assisted therapy is associated with a reduction in chronic pain among people with post-traumatic stress disorder (Frontiers)

Second MAPS-Sponsored Phase 3 Trial of MDMA-Assisted Therapy for PTSD Completed (MAPS)

Finland grants license for psychedelic drug therapy study (YLE)

Apollopact.org

Psychedelic Storytelling: Transforming Out Loud, featuring: Cory Firth (Psychedelics Today)

German Government Funds Psilocybin Study for Depression (Mind and Brain Institute)

LSD Research Ramps Up: Full-Dose & Microdosing For Alzheimer’s Studies Led By Beckley Foundation Coming Soon (Benzinga)

Chris Hemsworth Learned He Has a High Alzheimer’s Risk: What to Know (Healthline)

Posted on July 8, 2022October 4, 2022

PT335 – Christopher Dawson & Andrew Galloway – Modernizing Traditional Plant Medicine With Neuroscience and Luxury

In this episode, Joe interviews Christopher Dawson & Andrew Galloway: Co-Founders and CEO and COO, respectively, of Dimensions; a Canadian-based company creating retreats that blend traditional plant ceremonies with neuroscience and a luxurious, five-star environment.

Dawson realized what so many people were starting to learn about psychedelics after attending a 2015 conference in Peru that mixed neuroscientists with traditional healers, but for Galloway, it was direct experience, as he gives credit to plant medicines for helping him to heal from a 6-year addiction to crack cocaine. They each tell their story and how it led to the beginnings of Dimensions, where they worked for a year with a “Dreamlab” team of MDs, psychiatrists, practitioners from different fields, and even a design agency to create different programs for different substances – all with a focus on true set and setting and integrating perfectly with nature. They’re in the middle of a soft launch right now, offering cannabis in a ceremonial, group setting context to friends and families at their Algonquin Highlands location; perfecting everything before opening up to the general public. And once the law catches up with them, they hope to offer psilocybin and other psychedelic-assisted therapy across several new retreat locations. 

They talk about Health Canada and the country’s trajectory towards legal psychedelics; critiques of traditional addiction treatment and the efficacy of 12-step programs; the tension between the psychedelic space and traditional healing space; investing in biotech; the polyvagal theory; how animals deal with trauma (and how we don’t); and the concept of integration: If you’re just taking a pill and not doing the work, are you missing the point entirely?

Notable Quotes

“We’re biased (we’re in the retreat business), but I don’t think that psilocybin, as an example, should be reduced to a pill that you take with your juice in the morning and you no longer take your SSRI because this is your new pill. For us, it’s the psychedelic-assisted therapy that actually maximizes the potential of the psychedelic experience, and that’s the mechanisms through which fundamental, behavioral change can take place. I think the idea that a pill can replace all of that means that you’re kind of missing the point about the whole experience.” -Chris

“I don’t want to slam traditional treatment because it actually did work for me to some degree. …I had a crack-cocaine addiction for six-seven years and ended up in rehab for six months and came back and participated in 12-step programs and remained abstinent. That part worked. The difference for me when I got involved with plant medicine was something else: I got healed. Instead of just abstaining and not using to cope or to manage with whatever I was dealing with, I actually healed through plant medicine.” -Andrew

“Is it a pill or is it the therapeutic process? If you don’t engage in integration, then you’re just taking a pill.” -Chris

“We talked about stigma earlier; it’s changing, and [for] the general public, the stigma around the war on drugs is changing too. I think people have finally figured out that it doesn’t work. No war works. We only declare war on things that we can make money from.” -Andrew

Links

Dimensionsretreats.com

Dimensionsretreats.com: Algonquin Highlands

Psychedelics Today: PT314 – Daniel McQueen, MA – Vital Psychedelic Conversations

Psychedelics Today: Canada’s SAP Expansion Signals a Step Forward for Psychedelics

Dimensionsretreats.com: Dimensions + Queen’s University

Thedesignagency.ca

National Library of Medicine: Psychedelic perceptions: mental health service user attitudes to psilocybin therapy

Somaticmovementcenter.com: What is the Polyvagal Theory?

Psychedelics Today: PT248 – Pierre Bouchard – Somatic Therapy, Trauma, and the Nervous System (more about the polyvagal theory)

Psychedelicmedicinecoalition.org

About Christopher Dawson

Christopher Dawson is the Co-Founder and CEO of Dimensions, a growing collection of retreat destinations combining neuroscientific research with plant ceremony in immersive natural environments. Prior to co-founding Dimensions, Christopher was the founder and CEO of Edgewood Health Network, where he oversaw the largest private network of residential/outpatient treatment providers in Canada and led the merger and acquisition of Canada’s top three treatment centers to create that network.

 

About Andrew Galloway

Andrew Galloway is the Co-Founder and COO of Dimensions, a new paradigm for healing, combining ancient ceremonial plant medicines with modern science in safe, legal, and nurturing natural environments. He leads the organization’s clinical teams and operations for Dimensions Retreats, a new collection of immersive, transformational healing retreats combining neuroscientific research with plant ceremony and luxurious hospitality. Prior to co-founding Dimensions, he was a National Director of Edgewood Health Network; leading 10 outpatient centers. Andrew was the former VP at GreeneStone Muskoka, an international certified alcohol and drug counsellor, and has 14 years of experience working directly for the NHL/NHLPA substance abuse program.

Support the show!

  • Patreon
  • Leave us a review on Facebook or iTunes
  • Share us with your friends
  • Join our Facebook group – Psychedelics Today group – Find the others and create community.

Navigating Psychedelics


Posted on June 28, 2022October 4, 2022

PT332 – James Lanthier – Patentability, Capitalism, and The Next Generation of Psychedelics

In this episode of the podcast, Joe interviews the CEO of Mindset Pharma, James Lanthier.

Mindset Pharma is a 3-year old biotechnology company built on discovering and developing new psychedelic compounds to be used as medicine for a variety of indications. While the efficacy of the psychedelics we know can’t be denied, the goal of science is to improve, and Lanthier believes optimizing these drugs will make them safer, more predictable, and more palatable for a far greater portion of the population. He envisions these new molecules leading to a future of highly personalized medicine, where people who would never eat a mushroom would likely take a related drug prescribed by their doctor.

Lanthier discusses what’s going on at Mindset Pharma; why patents alone will not be sufficient protection from competition; the long game of biotech, psychedelic stocks, and overreaction to slow growth; the Nagoya protocol; mescaline; the need for big pharma and capitalism; the art of formulation; and how microdosing could soon be revolutionized. 

Notable Quotes

“I had some fairly well-known psychedelic investors say to me, ‘You’re just building a better mousetrap.’ And my reaction was: ‘Well, that’s the march of science. That’s what science is trying to do.’ Take the example of what the German scientist [Felix Hoffman] did in the nineteenth century to go from the bark of the willow tree, eventually going through a whole bunch of intermediate chemical steps to eventually get to Aspirin. Science hopefully tries to make things better, and that’s what we’re trying to do.”

“Big pharma has skipped right past psilocybin. Why? In my view, it would be because of the lack of strong IP rights. They’ve gone right to second and third generation drugs because they’ve made the assessment that even if you own the strongest IP in the psilocybin space, you’re still quite exposed, ultimately, to competition.”

“I think if there’s a future where you have relatively low-priced classic drugs potentially available alongside more optimized, specific drugs that have the full support of the medical community, that would be a great place to get to, I think – really great place to get to. And I think we only really get there with the machinery of capitalism moving forward.”

Links

Mindsetpharma.com

Otsuka-us.com (Otsuka Pharmaceutical)

Sciencehistory.org: Felix Hoffman

YouTube: Dr. Stanislav Grof, “Psychedelics and the Future of Humanity”, MAPS Psychedelic Science 2017

Protests for Right to Try (sent to us by Kathryn Tucker)

Nagoya Protocol

About James Lanthier

James Lanthier is the CEO of Mindset Pharma, and is a seasoned technology executive with strong expertise in corporate finance, public markets and M&A. Most recently, Mr. Lanthier was a co-founder and CEO of Future Fertility, an innovative early stage developer of AI applications for human infertility. As a C-Suite executive, Mr. Lanthier has assisted in the growth and successful exit of numerous technology-enabled businesses through the public markets, including Mood Media, the world’s largest in-store media provider, and Fun Technologies, a pioneer in online casual games.

Socials: Linkedin


Support the show!

  • Patreon
  • Leave us a review on Facebook or iTunes
  • Share us with your friends
  • Join our Facebook group – Psychedelics Today group – Find the others and create community.

Navigating Psychedelics

Posted on June 24, 2022October 4, 2022

PT331 – Julie Zukof & Dr. Michelle Weiner – Psychedelic Women, Coaching, and Ketamine For Fibromyalgia

In this episode, Joe interviews Julie Zukof: Head of Strategic Partnerships for Nue Life and the creator of Psychedelic Women, and Michelle Weiner: a double board-certified Doctor specializing in integrative pain management, using cannabis, ketamine, and other holistic modalities to get to the root cause of chronic pain.

Weiner tells of how her pain-management methods changed as her patients told her about the healing power of cannabis and ketamine, and how she was even more inspired by learning how much chronic pain is a result of fight-or-flight trauma reactions and resulting learned behavior. She discusses the central sensitization of fibromyalgia; ketamine infusions and dose discovery; the differences between how therapists and coaches are viewed (and the need for both); session music and trusting the facilitator in their music choice; and the importance of preparing for a ketamine experience through meditation and/or breathwork. 

And they talk about Psychedelic Women, which was just founded in January as a result of Zukof realizing how much women were a minority in the psychedelic space. She talks about why we need more women in psychedelia; women’s natural inclination to connect and support each other; and how medicine should mirror that – where people from all methodologies can work together for the betterment of the patient. Psychedelic Women is in the process of updating from a speaker series to a more community-based platform. If you want to become a part of the community, sign up at their waitlist today!

Notable Quotes

“Personally, the coaches and the therapists that I use (my nurse practitioners) are mainly women. And I don’t know if that’s because they gravitate towards this field or because patients gravitate towards them, but there’s that nurturing, innate property of being a woman that also is special and unique and we can use to our advantage in that sense.” -Michelle

“I think people are under the impression that psychedelics are always meant to be enjoyable. And while ketamine oftentimes is enjoyable, sometimes it’s meant to be part of a healing journey.” -Julie

“I credit Dustin [Robinson] for bringing us on and featuring the group at Soho House, and something he said was, ‘It’s not that I don’t want to feature women on the panel, I just need more women in the space to feature them.’ And I think that’s an excellent point. And if we can help do something about that, then I think we’re winning.” -Julie

“There’s so many other people that are involved in making this experience more effective for people. It’s not just the medicine and the doctor and the therapist and the coach. …It’s so nice to see because this is really how medicine should be. It shouldn’t be everybody in their own box like with other physicians. …This whole group is really bringing people together that have certain talents and passions and saying: ‘We can work together.’” -Michelle

Links

Psychedelicwomen.co

DrMichelleWeiner.com

Msha.ke: Julie Zukof

Nue.life

Spinewellnessamerica.com

Citybiz.co: Dustin Robinson Presents Psychedelic Women Panel, Part of the Monthly Psychedelic Series at Soho Beach House Miami on Jan. 17

Psychiatryadvisor.com: Pain Reprocessing Therapy Reduces Pain Perception, Disability in Chronic Back Pain

Wavepaths.com

Psychedelics Today: PTSF 41 (with Mendel Kaelen of Wavepaths)

Chief.com

Heymama.co

Dreamersdoers.com

“Psychedelics & Pain Symposium” event by REMAP Therapeutics (this event is tomorrow!)

Stanford Psychedelic Science Group

UC San Diego: Psychedelics and Health Research Initiative

About Julie Zukof

Julie Zukof is the creator of Psychedelic Women, a speaker series and influential community. Over her eighteen year career in NYC, Julie has created, innovated, marketed, and grown wellness brands by working at prestigious innovation firms and then starting her own consultancy. Julie is now Head of Strategic Partnerships for Nue Life, the leading mental wellness company in at-home ketamine treatments.

 

Socials:

Instagram / Linkedin

 


About Dr. Michelle Weiner, DO MPH

Dr. Michelle Weiner is double board-certified in Interventional Pain Medicine and Physical Medicine and Rehabilitation, and a partner in private practice at Spine and Wellness Centers of America. She is a member of Florida’s Medical Cannabis Advisory Committee, vice president of Mr. Psychedelic Law, a not-for-profit with the mission of responsible legal reform of psilocybin, and a clinical advisor for Iter Investments, a venture capital firm focused on supporting emerging companies within the psychedelic ecosystem of behavioral and mental health. Dr. Weiner’s research focuses on using cannabis as a substitute for opioids in chronic pain patients and cannabis’s effect on seniors with chronic pain, as well as comparing psychedelic v psycholytic doses of ketamine for chronic pain and depression. Her unique approach of personalized and preventative medicine focuses on empowering her patients to cultivate health using cannabis and ketamine-assisted psychotherapy as a catalyst to identify the root cause of one’s suffering, optimizing their quality of life.

Socials: Instagram 

 

Support the show!

  • Patreon
  • Leave us a review on Facebook or iTunes
  • Share us with your friends
  • Join our Facebook group – Psychedelics Today group – Find the others and create community.

Navigating Psychedelics

Posted on May 24, 2022October 4, 2022

PT321 – Lyle Maxson – Virtual Reality, Biofeedback, and Digital Therapeutics: The Future of Mental Health

In this episode of the podcast, Joe interviews Lyle Maxson: Co-Founder and Chief Strategy Officer of Entheo Digital, a “technodelic” company focusing on digital therapeutics and virtual reality – both as adjuncts to psychedelic-assisted therapy, and theoretically, as new forms of medicine.  

Maxson began his career by creating immersive, psychedelic-like experiences at some of the world’s largest music festivals. It was mostly those world-building experiences and some time in sensory deprivation tanks that led to his interest in seeing just what was possible through altered states of consciousness and technology. He discusses using VR before and after psychedelic experiences as a priming and integration tool; VR’s potential to ease first-time trip anxiety; Entheo Digital’s SoundSelf system and the powerful influence of biofeedback; and the question of whether or not technology (on its own) could initiate a non-ordinary state of consciousness with the same benefits as one brought on by psychedelics. 

This episode treads lots of new ground, with Maxson discussing the likelihood of using different tools to be able to naturally activate endogenous DMT; the idea of a Steam-like internet marketplace for digital medicine; the possibility for technology to trigger lucid dreaming; the concept of highly-personalized digital schooling, and the tough question of how to not become so reliant on technology in such a quickly-advancing technological world. The challenge, which Maxson is eager to take on, is to shift opinions on VR from fear and pessimism to inspiration about what’s truly possible: How can we use technology not for escapism, but instead, for good?

Notable Quotes

“If you’re trying to drive to a yoga class, you’re usually more stressed out by the time you get there than if you hadn’t of left your house at all. And I feel like that’s the case with a lot of therapy work in general, whether it’s psychedelics or not; you could have [an] onboarding call with somebody the day before, but you have no idea what’s happening to them [in] the 24 hours leading up to them actually coming into your clinic. So I think the big focus on the priming is: how do we have reliable, very consistent treatment processes with being able to drop people into a very deep surrender, meditative, introspective state prior to them actually going into a therapeutic process?”

“I think that eventually, you’ll start to combine light, frequency, vibration, [and] electromagnetics to the point where you could actually activate DMT inside of your brain without having to use it from an external source – so like, literally using technology to activate the psychedelics inside of your own body. I think we will get to that place and that will be very interesting.”

“What [we’re] doing with creating digital medicine is a holy grail type of project, but with that comes the reverse side; which is the addiction that we already have to computers is off the charts, but what happens when you could literally press play and get high at any moment? Would people ever get off of it? So that’s a philosophical question, but I think we’re actually going to butt up against that in the next few years as we continue to develop this technology.”

“What does it look like to get in on the ground floor? It’d be really hard to do that in movies or radio or the variety of mediums; TV shows, all of those things. Like, they’re already pretty much dominated by content that we don’t really want or doesn’t make us feel better when we watch it. But with VR, it’s early enough to get in on the ground floor and create compelling alternatives to the zombie shooter games and the porn that will inevitably fill the device, and get people thinking about how to be an embodied avatar inside of a virtual world and do it for good instead of for escapism.”

Links

Lylemaxson.com

Entheo.digital

Soundself.com

Geniusx.com

Guide to Topanga Canyon: A Piece of Hippie Heaven

Thetawellness.com

Truerestfranchising.com: Nick Janicki

Spiritualtechnologies.io: Don Estes

Pandorastar.co.uk

FDA.gov: FDA Permits Marketing of First Game-Based Digital Therapeutic to Improve Attention Function in Children with ADHD

Othership.us (Robbie Bent)

Enterandromeda.com (Andromeda Entertainment)

What Technology Wants, by Kevin Kelly

The Tim Ferriss Show: Interview with Peter Thiel, Billionaire Investor and Company Creator (#28)

Reality Is Broken: Why Games Make Us Better and How They Can Change the World, by Jane McGonigal

MicrodoseVR.com

Exploredeep.com (Deep VR)

AppliedVR.io (Applied VR)

Breathscape.com

About Lyle Maxson

Lyle Maxson is the Co-Founder of GeniusX, an XR education platform reimagining online learning. He is also the Co-Founder of Andromeda Entertainment, a VR publishing company focused on bringing to market “games for good,” which developed and published the first-ever digital psychedelic, Soundself VR, as well as the breakout hit, Audio Trip (voted best dance game of 2019 by VR insider). His latest venture, Entheo Digital, seeks to provide digital therapeutics solutions for psychedelic therapy and the treatment of mental health disorders. Lyle has appeared on a variety of stages, speaking on benevolent technology and the positive impact immersive tech can play in our future. He runs a 50,000 person community of transformative entertainment enthusiasts and is a pioneer in the neurohacking movement.

Socials: Instagram / LinkedIn 


Support the show!

  • Patreon
  • Leave us a review on Facebook or iTunes
  • Share us with your friends
  • Join our Facebook group – Psychedelics Today group – Find the others and create community.

Navigating Psychedelics

Posted on May 20, 2022October 4, 2022

PT320 – Anne Philippi – The New Health Club, Intergenerational Trauma, and Psychedelics in the Workplace

In this episode of the podcast, David interviews Anne Philippi; Founder & CEO of The New Health Club. Prior to her work with TNHC, Anne was a journalist for VOGUE, GQ, and Vanity Fair.

Philippi takes us through the arc of her departure from the media world in 2018 and into the realm of psychedelia. She opens up about her first experiences with LSD and psilocybin; how those journeys helped her shake off her “old narrative” as a journalist and step into her “real narrative”; the podcast that was birthed out of that inner work and its transformation into a business; and the work TNHC now does with ketamine and psilocybin truffles. Along with her personal story, she talks about things like integration; how the meaning of symbols witnessed in journeys becomes clearer over time; generational trauma (especially as experienced by Germans); non-linear healing; and how modern data pertaining to psychedelics is outshining the hangover from the US’s drug war propaganda.

Using the current COVID era and Ukraine/Russia conflict as examples, Philippi shares how crises can inspire togetherness and the importance of making psychedelic therapy available to refugees. She takes a very optimistic stance on the incorporation of psychedelics into the workplace as a means to help it evolve, and she talks about the toxicity of hustle culture; how safe, supported psychedelic practices can prevent burnout in the workforce; the companies that are already offering psychedelic experiences and therapy for their staff; and the value in entertaining psychedelics as a preventative measure – not just a recuperative treatment.

Notable Quotes

“I really think that with a psychedelic experience, or a regular checking in with [yourself] based on that psychedelic experience (maybe even to go on a guided trip [once or twice] a year), it’s really easier to acknowledge your body, to have a conversation with your body. Because we don’t say, ‘I’m tired, I feel like I need to take a break’; we mostly overstep that moment because then you have another coffee or you go for a run – all these tools we have in our Western society to ignore our exhaustion limits.”

“Let’s say you have an amazing psychedelic trip, and then you go back to your shitty life and you don’t change that, and you don’t go in nature, and you don’t have a community, and you’re in a toxic relationship – then the trip doesn’t actually matter in a weird way. I think that’s also something that is becoming now very clear; that the surrounding where you actually land after your trip also has to be transformed.”

“I think in the next five years, there might be completely transformed companies coming out of a psychedelic leadership idea. And again, that doesn’t mean the crazy CEO who is going crazy on ayahuasca, it’s just really to have a very conscious use of these substances, to really look into a better understanding of a very productive and creative community that is not suffering from [a] toxic work environment anymore.” 

“You can find this kind of truth with the help of psychedelics. The people who I have talked to who have experienced that, whatever substance it is …pretty much, that’s the bottom line [of] what people say. At the same time, we should not really forget to say those people who found that had also done a proper integration and keep doing it, even after months and months of experiencing what they have seen.”

Links

Thenewhealthclub.de

Synthesisretreat.com

How to Change Your Mind: What the New Science of Psychedelics Teaches Us about Consciousness, Dying, Addiction, Depression, and Transcendence, by Michael Pollan

Condenast.com

APX.vc

Fieldtriphealth.com

About Anne Philippi

Anne Philippi was a successful journalist with a strong background in established media, journalism, and communication. She published books, worked for Condé Nast, was a Vanity Fair reporter in Berlin and for GQ in Los Angeles, and she wrote for Frankfurter Allgemeine Zeitung about tech and California. ‍In 2019, she founded The New Health Club podcast and newsletter, and created a space where CEOs, founders, investors, scientists, and therapists from the new psychedelic ecosystem and business world could talk abut the disruptive power of psychedelics, new markets, new compounds, and psychedelic medicine. In 2021, Anne made it onto Psychedelic Invest‘s list of the 100 most influential people in psychedelics. She is working on bringing The New Health Club to the next level soon.

Socials: Instagram / Twitter / LinkedIn 


Support the show!

  • Patreon
  • Leave us a review on Facebook or iTunes
  • Share us with your friends
  • Join our Facebook group – Psychedelics Today group – Find the others and create community.

Navigating Psychedelics

Posts navigation

Page 1 Page 2 … Page 6 Next page

Keeping Tabs

A microdose of all things psychedelic news, all in one place. Get bi-weekly updates, education, and events straight to your inbox.

We won’t share your information. Unsubscribe at any time.

pt_logo_white (1)

Psychedelics Today is the planetary leader in psychedelic media, storytelling, and education.

Menu
  • Podcasts
  • Articles
  • Events
  • About
  • Press
  • Contact
Subscribe to our newsletter
Visit Our Other Sites
  • Education Center
  • Vital
  • Shop
Subscribe to our Podcast
© Psychedelics Today. All rights reserved. Privacy | Terms & Conditions